Afimkibart Clinical Trials
7 recruitingDrug
Phase 34Phase 23
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche100 enrolled9 locationsNCT07158242
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche425 enrolled167 locationsNCT06819891
Recruiting
Phase 2
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Atopic Dermatitis
Hoffmann-La Roche120 enrolled7 locationsNCT07223697
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Hoffmann-La Roche160 enrolled69 locationsNCT06863961
Recruiting
Phase 2
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Rheumatoid Arthritis
Hoffmann-La Roche160 enrolled32 locationsNCT07137598
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Moderately to Severely Active Crohns Disease
Hoffmann-La Roche600 enrolled355 locationsNCT06819878
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche350 enrolled198 locationsNCT06588855